Literature DB >> 33284890

Circular RNA circ_ASAP2 promotes cell viability, migration, and invasion of gastric cancer cells by regulating the miR-770-5p/CDK6 axis.

Bing Chen1, Fei Ji2, Xinian Wen3, Zhong Jin4.   

Abstract

BACKGROUND: Gastric cancer (GC) is one of the most common causes of cancer death. GSE83521 microarray analysis suggested that circular RNA circ_ASAP2 (hsa_circ_0008768) expression was increased in GC tissues. However, the molecular mechanism of circ_ASAP2 remains unknown.
METHODS: Expression levels of circ_ASAP2, microRNA-770-5p (miR-770-5p), and the cyclin-dependent kinase 6 (CDK6) were detected by using real time PCR (RT-PCR). 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and transwell assays were applied to explore cell viability, migration, and invasion, respectively. The interactions between miR-770-5p and circ_ASAP2 or CDK6 was predicted by using Starbase software, and then confirmed by luciferase reporter assay. Xenograft tumor model was also used to estimate the effect of circ_ASAP2 on tumor growth in vivo.
RESULTS: The expression levels of circ_ASAP2 and CDK6 were increased, and miR-770-5p level was decreased in GC tissues and cells. Furthermore, circ_ASAP2 knockdown inhibited cell viability, migration, and invasion of GC cells. Mechanically, circ_ASAP2 functioned as a sponge of miR-770-5p to regulate CDK6 expression, thereby boosting the progression of GC cells. Circ_ASAP2 silencing hindered the tumor growth of GC in vivo.
CONCLUSION: Circ_ASAP2 knockdown can repress the development of GC cells partly through regulating the miR-770-5p/CDK6 axis, suggesting an underlying circRNA-targeted therapy for GC treatment. IJCEP
Copyright © 2020.

Entities:  

Keywords:  CDK6; Gastric cancer; circ_ASAP2; miR-770-5p

Year:  2020        PMID: 33284890      PMCID: PMC7716128     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  41 in total

1.  Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation.

Authors:  Eric C Lai
Journal:  Nat Genet       Date:  2002-03-18       Impact factor: 38.330

2.  miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop.

Authors:  Min Deng; Chao Zeng; Xihong Lu; Xiusheng He; Ruixin Zhang; Qinwei Qiu; Guopei Zheng; Xiaoting Jia; Hao Liu; Zhimin He
Journal:  Cancer Lett       Date:  2017-06-17       Impact factor: 8.679

3.  miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells.

Authors:  Li Feng; Yun Xie; Hao Zhang; Yunlin Wu
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

4.  MicroRNA (miRNA) in cancer.

Authors:  Kaladhar B Reddy
Journal:  Cancer Cell Int       Date:  2015-04-02       Impact factor: 5.722

5.  Downregulation of microRNA‑33a promotes cyclin‑dependent kinase 6, cyclin D1 and PIM1 expression and gastric cancer cell proliferation.

Authors:  Yudong Wang; Xinliang Zhou; Baoen Shan; Jing Han; Feifei Wang; Xiaojie Fan; Yalei Lv; Liang Chang; Wei Liu
Journal:  Mol Med Rep       Date:  2015-09-07       Impact factor: 2.952

6.  Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells.

Authors:  Daguang Wang; Yabin Sun; Wei Li; Fei Ye; Yang Zhang; Yuchen Guo; David Y Zhang; Jian Suo
Journal:  Int J Mol Med       Date:  2018-02-06       Impact factor: 4.101

7.  A circRNA-miRNA-mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma.

Authors:  Dan-Dan Xiong; Yi-Wu Dang; Peng Lin; Dong-Yue Wen; Rong-Quan He; Dian-Zhong Luo; Zhen-Bo Feng; Gang Chen
Journal:  J Transl Med       Date:  2018-08-09       Impact factor: 5.531

8.  circZNF609 promotes the proliferation and migration of gastric cancer by sponging miR-483-3p and regulating CDK6.

Authors:  Weidong Wu; Ningxian Wei; Gang Shao; Chunnan Jiang; Shaoru Zhang; Lihui Wang
Journal:  Onco Targets Ther       Date:  2019-10-04       Impact factor: 4.147

Review 9.  Circular RNAs in cancer: opportunities and challenges in the field.

Authors:  L S Kristensen; T B Hansen; M T Venø; J Kjems
Journal:  Oncogene       Date:  2017-10-09       Impact factor: 9.867

10.  Long noncoding RNA MACC1-AS1 is a potential sponge of microRNA-34a in cervical squamous cell carcinoma and upregulates cyclin-dependent kinase 6.

Authors:  Jieqiong Jin; Xuemei Chen; Jing Chen; Xin Geng
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

View more
  6 in total

1.  Circ ASAP2 decreased inflammation and ferroptosis in diabetic nephropathy through SOX2/SLC7A11 by miR-770-5p.

Authors:  Qin Li; Xiangjian Meng; Qiang Hua
Journal:  Acta Diabetol       Date:  2022-09-24       Impact factor: 4.087

2.  Circ_0008035 promotes the progression of gastric cancer via the regulation of miR-1256/CEACAM6 axis.

Authors:  Chaoyang Chu; Xianli Liu; Zhiguo Zhao; Zhijie Shi
Journal:  Cell Cycle       Date:  2022-02-28       Impact factor: 5.173

3.  Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer.

Authors:  Souvick Roy; Mitsuro Kanda; Sachiyo Nomura; Zhongxu Zhu; Yuji Toiyama; Akinobu Taketomi; James Goldenring; Hideo Baba; Yasuhiro Kodera; Ajay Goel
Journal:  Mol Cancer       Date:  2022-02-09       Impact factor: 27.401

Review 4.  Circular RNA Controls Tumor Occurrence and Development via Cell Cycle Regulation.

Authors:  Fang Liu; Rongfeng Qu; Limin Yang; Guang Shi; Shuhong Hao; Chunmei Hu
Journal:  Onco Targets Ther       Date:  2022-09-15       Impact factor: 4.345

5.  A peptide translated from circPPP1R12A promotes the malignancy of non-small cell lung cancer cells through AKT signaling pathway.

Authors:  Weijun Zhao; Yibo Xue; Yandan Zhang; Yonggang Zhu; Zixuan Chen; Xiaodong Zhao
Journal:  J Clin Lab Anal       Date:  2022-08-21       Impact factor: 3.124

6.  The circular RNA circ_GRHPR promotes NSCLC cell proliferation and invasion via interactions with the RNA-binding protein PCBP2.

Authors:  Yanyan Hou; Jiafei Lin; Danyang Wang; Yingwei Zhang; Qiuli Liang; Ning Chen; Jiemin Wu; Weiqi Wu; Xiangfan Liu; Peihua Ni
Journal:  Clin Exp Pharmacol Physiol       Date:  2021-05-29       Impact factor: 2.557

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.